SOD1 and amyotrophic lateral sclerosis: To this end the ALS Therapy Development Institute has independently assessed prior reports of pre-clinical efficacy in mutant SOD1 mice and after assessing many other candidates the copper-containing compound CuII(atsm) is the first putative treatment option that the ALS Therapy Development Institute has been able to validate6.